Picture loading failed.

Anti-MSLN therapeutic antibody (Pre-made Anetumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Anetumab ravtansine, here referred to as BAY 94-9343, a novel ADC consisting of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4 via a disulfide-containing linker.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-025-1mg 1mg Inquiry
GMP-Bios-ab-025-10mg 10mg Inquiry
GMP-Bios-ab-025-100mg 100mg Inquiry
GMP-Bios-ab-025-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-MSLN therapeutic antibody (Pre-made Anetumab biosimilar,Whole mAb ADC)
INN Name Anetumab
FormatWhole mAb ADC
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesBayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA)
Conditions Approvedna
Conditions ActiveLung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer;Malignant thymoma
Conditions DiscontinuedFallopian tube cancer;Peritoneal cancer
Development TechMorphoSys HuCAL Phage Display